Literature DB >> 8952536

Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.

M Gambacorta1, L Flenghi, M Fagioli, S Pileri, L Leoncini, B Bigerna, R Pacini, L N Tanci, L Pasqualucci, S Ascani, A Mencarelli, A Liso, P G Pelicci, B Falini.   

Abstract

The RING-finger promyelocytic leukemia (PML) protein is the product of the PML gene that fuses with the retinoic acid receptor-alpha gene in the t(15; 17) translocation of acute promyelocytic leukemia. Wild-type PML localizes in the nucleus with a typical speckled pattern that is a consequence of the concentration of the protein within discrete subnuclear domains known as nuclear bodies. Delocalization of PML from nuclear bodies has been documented in acute promyelocytic leukemia cells and suggested to contribute to leukemogenesis. In an attempt to get new insights into the function of the wild-type PML protein and to investigate whether it displays an altered expression pattern in neoplasms other than acute promyelocytic leukemia, we stained a large number of normal and neoplastic human tissues with a new murine monoclonal antibody (PG-M3) directed against the amino-terminal region of PML. As the PG-M3 epitope is partially resistant to fixatives, only cells that overexpress PML are detected by the antibody in microwave-heated paraffin sections. Among normal tissues, PML was characteristically up-regulated in activated epithelioid histiocytes and fibroblasts in a variety of pathological conditions, columnar epithelium in small active thyroid follicles, well differentiated foamy cells in the center of sebaceous glands, and hypersecretory endometria (Arias-Stella). Interferons, the PML of which is a primary target gene, and estrogens are likely to represent some of the cytokines and/or hormones that may be involved in the up-regulation of PML under these circumstances. In keeping with this concept, we found that PML is frequently overexpressed in Hodgkin and Reed-Sternberg cells of Hodgkin's disease, a tumor of cytokine-producing cells. Among solid tumors, overexpression of PML was frequently found in carcinomas of larynx and thyroid (papillary), epithelial thymomas, and Kaposi's sarcoma, whereas carcinomas of the lung, thyroid (follicular), breast, and colon were frequently negative or weakly PML+. We did not observe any changes in the levels of PML expression as the lesion progressed from benign dysplasia to carcinoma. Our immunohistological data are consistent with the hypothesized growth suppressor function of PML and strongly suggest that PML expression levels are likely to be modulated by a variety of stimuli, including cytokines and hormones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952536      PMCID: PMC1865355     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

Review 1.  Nuclear bodies (NBs): a newly "rediscovered" organelle.

Authors:  K Brasch; R L Ochs
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

2.  Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections.

Authors:  G Cattoretti; S Pileri; C Parravicini; M H Becker; S Poggi; C Bifulco; G Key; L D'Amato; E Sabattini; E Feudale
Journal:  J Pathol       Date:  1993-10       Impact factor: 7.996

3.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.

Authors:  J A Dyck; G G Maul; W H Miller; J D Chen; A Kakizuka; R M Evans
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells.

Authors:  F Grignani; P F Ferrucci; U Testa; G Talamo; M Fagioli; M Alcalay; A Mencarelli; F Grignani; C Peschle; I Nicoletti
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

Review 5.  Acute promyelocytic leukemia: from genetics to treatment.

Authors:  F Grignani; M Fagioli; M Alcalay; L Longo; P P Pandolfi; E Donti; A Biondi; F Lo Coco; F Grignani; P G Pelicci
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

6.  Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.

Authors:  K Weis; S Rambaud; C Lavau; J Jansen; T Carvalho; M Carmo-Fonseca; A Lamond; A Dejean
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

7.  PML protein expression in hematopoietic and acute promyelocytic leukemia cells.

Authors:  M T Daniel; M Koken; O Romagné; S Barbey; A Bazarbachi; M Stadler; M C Guillemin; L Degos; C Chomienne; H de Thé
Journal:  Blood       Date:  1993-09-15       Impact factor: 22.113

8.  Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).

Authors:  G G Maul; H H Guldner; J G Spivack
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

9.  Nuclear dot antigens may specify transcriptional domains in the nucleus.

Authors:  K Xie; E J Lambie; M Snyder
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

10.  Cell type- and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55.

Authors:  Y W Lam; W Ammerlaan; W S O; F Kroese; D Opstelten
Journal:  Exp Cell Res       Date:  1995-12       Impact factor: 3.905

View more
  28 in total

1.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

2.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein.

Authors:  Zhipeng Xu; Jiamin Chen; Liming Shao; Wangqian Ma; Dingting Xu
Journal:  Tumour Biol       Date:  2015-05-15

4.  HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation.

Authors:  Meisheng Yu; Jishi Wang; Dan Ma; Shuya Chen; Xiaojing Lin; Qin Fang; Nana Zhe
Journal:  Oncol Lett       Date:  2015-08-26       Impact factor: 2.967

Review 5.  The role of PML in the nervous system.

Authors:  Paolo Salomoni; Joanne Betts-Henderson
Journal:  Mol Neurobiol       Date:  2010-12-15       Impact factor: 5.590

6.  Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells.

Authors:  Sona Hubackova; Katerina Krejcikova; Jiri Bartek; Zdenek Hodny
Journal:  J Biol Chem       Date:  2012-06-18       Impact factor: 5.157

7.  Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.

Authors:  Eunsil Yu; Eun Kyung Choi; Chong Jai Kim
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

Review 8.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

9.  Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma.

Authors:  Kazuyuki Kuwayama; Kazuhito Matsuzaki; Yoshihumi Mizobuchi; Hideo Mure; Keiko T Kitazato; Teruyoshi Kageji; Mitsuyoshi Nakao; Shinji Nagahiro
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

10.  PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.

Authors:  Akio Iwanami; Beatrice Gini; Ciro Zanca; Tomoo Matsutani; Alvaro Assuncao; Ali Nael; Julie Dang; Huijun Yang; Shaojun Zhu; Jun Kohyama; Issay Kitabayashi; Webster K Cavenee; Timothy F Cloughesy; Frank B Furnari; Masaya Nakamura; Yoshiaki Toyama; Hideyuki Okano; Paul S Mischel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.